NumerixS Investment Technologies’s Intellia Therapeutics NTLA Stock Holding History

NumerixS Investment Technologies’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-11,100	Closed	-$163K	–	1193
2019 Q4	$163K	Buy	11,100 +2,500	+29%	+$34.8K	0.03%	546
2019 Q3	$115K	Buy	8,600 +4,000	+87%	+$63.8K	0.03%	524
2019 Q2	$75K	Sell	4,600 -2,000	-30%	-$31.4K	0.02%	681
2019 Q1	$110K	Buy	+6,600	New	+$98.4K	0.01%	844
2018 Q4	–	Sell	-2,562	Closed	-$74K	–	1277
2018 Q3	$74K	Sell	2,562 -7,238	-74%	-$211K	0.01%	886
2018 Q2	$265K	Buy	+9,800	New	+$237K	0.06%	429
2018 Q1	–	Sell	-2,500	Closed	-$48K	–	1209
2017 Q4	$48K	Buy	+2,500	New	+$57.7K	0.01%	871
2016 Q3	–	Sell	-5,500	Closed	-$117K	–	1246
2016 Q2	$117K	Buy	+5,500	New	+$146K	0.02%	842

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

NumerixS Investment Technologies's NTLA Position: Q1 2020 in Review

NumerixS Investment Technologies sold out of Intellia Therapeutics (NTLA) in Q1 2020, closing a stake of 11,100 shares — an estimated $163K sold.

NumerixS Investment Technologies first reported a position in NTLA in Q2 2016 and held it in 8 quarters. The position peaked at $265K in Q2 2018. 140 funds tracked by Wall St. Rank hold NTLA as of Q1 2020.

NumerixS Investment Technologies reported no remaining Intellia Therapeutics position as of Q1 2020 after selling out during the quarter.
NumerixS Investment Technologies sold 11,100 Intellia Therapeutics shares in Q1 2020, an estimated $163K.
NumerixS Investment Technologies first reported a position in Intellia Therapeutics in Q2 2016 and held it in 8 quarters.
NumerixS Investment Technologies's Intellia Therapeutics position peaked at $265K in Q2 2018.
140 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2020.

Based on NumerixS Investment Technologies's 13F filing for Q1 2020, filed 15 May 2020.